DAWES KAREN A 4

What Happened

• Karen A. Dawes, a director of Repligen Corporation (RGEN), received equity awards on May 14, 2026. The Form 4 reports 995 restricted stock units (RSUs) and 2,239 derivative units, each recorded at $0.00 (no cash paid). The awards are grants (code A) and not open‑market purchases or sales.

Key Details

• Transaction date: May 14, 2026; filing date: May 18, 2026 (Form 4).
• Reported amounts and price: 995 shares @ $0.00 (RSUs) and 2,239 shares (derivative) @ $0.00; total cash value reported = $0.
• Vesting: Awards vest in full on the earlier of May 14, 2027 (one year from grant) or the date of the next annual meeting of shareholders (date not yet determined). The RSUs may be settled only by delivery of common stock.
• Footnotes: The 995 RSUs represent contingent rights to receive one share per unit; vesting terms described above. The grant is reported in Table 1 per SEC guidance.
• Shares owned after the transaction: Not specified in the provided filing.
• Timeliness: The Form 4 was filed four days after the May 14 transaction (filed May 18); Form 4s are typically due within two business days, so this appears to be a delayed filing.

Context

• These awards are grants to a director and reflect compensation/retention rather than an outright market purchase or sale. RSU grants do not involve immediate cash flow and only convert to shares upon vesting and settlement. Such awards are common for directors and, by themselves, are not a direct buy/sell signal of the insider’s market view.